Research and Practice in Thrombosis and Haemostasis

Article	Citations
OC 03.2 Characterization of Peripheral Monocyte Subsets in a Prospective Cohort of Patients with Acute Stroke Suspicion: Results of BOOST Study	81
OC 14.2 Pharmacokinetic Characteristics of ADAMTS13 in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Interim Results from a Phase 3 Randomized, Controlled, Open-Label, Crossover Study	65
PB0464 Smaller Nadroparin Dose Reductions Required for Patients with Renal Impairment: A Multicenter Study	60
PB1228 Inhibitor Detection in Acquired Hemophilia A: A Comparison between the Nijmegen Modified Bethesda Assay and an Anti-FVIII ELISA	54
OC 45.3 Major Bleeding Event Rates in Patients on Hemodialysis and Peritoneal Dialysis: Results from the International DOPPS and PDOPPS	49
OC 42.5 Hemorrhagic Risk of Caplacizumab in the Treatment of Thrombotic Thrombocytopenic Purpura a Pharmacovigilance Study from 2020–2022 FAERS Database	49
OC 50.1 Levels of IgG4 Distinguish Immune Tolerance Induction Outcome in Patients with Inherited Hemophilia A: Results from the BrazIT Study	43
OC 71.5 Reasons for Anticoagulation Failure and Provider Management	43
OC 74.1 Circulating Biomarkers and Mortality in Atrial Fibrillation: The Reasons for Geographic and Racial Differences in Stroke Study	38
OC 71.4 Management Patterns of Antithrombotics and Outcomes in Patients with Hematological Malignancy and Thrombocytopenia: A Prospective Registry (Matter Study)	38
OC 75.1 First US Rare Bleeding Disorder Genotype-Phenotype Registry (ATHN 10) Discovers Many Individuals with Both Novel and Multiple Variants using a Customized 30-Gene Next-Generation Sequencing Pan	37
PB0046 Increased Platelet Activation Demonstrated by Elevated CD36 and P-Selectin Expression in 1-year Post Recovered COVID-19 Patients	36
OC 53.5 Clinical Outcomes in Patients with Acute Pulmonary Embolism Undergoing Ultrasound-Assisted Catheter-Directed Thrombolysis	35
OC 61.3 CS585 is a Novel and Highly Selective IP Receptor Agonist for Prevention of Thrombosis	35
PB0074 Hyper-Immunoglobulin-CovImmuneTM, Provides a Broader Coverage Against Diverse SARS-CoV-2 Variants Relevant to the COVID-19 Pandemic	34
PB0926 Venous Thromboembolism and Risk of Depression in Patients with Hematological Cancer: A Population-Based Cohort Study	32
PB0957 The Application of Existing Risk Assessment Models (RAMs) to Predict the Occurrence of Venous Thromboembolic Events among Patients with Classic Hodgkin's Lymphoma	30
PB1031 Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC: KVAD Study	28
Exploration of biomarkers for inhibitor development in persons with hemophilia A	28
Issue Information	28
Erratum to ‘A comparative study in type 2 von Willebrand disease patients using four different platelet-dependent von Willebrand factor assays.’ [Research and Practice in Thrombosis and Haemostasis Vo	27
Navigating the inevitable: artificial intelligence and the future of scientific communication	27
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3	26
PB0715 H3 Alters the Behavior of Endothelial Cells In Vitro	26
PB0679 Clinical Characteristics and Disease Outcomes in Previously Treated Patients with Haemophilia: Results from a Real-World Study in Europe and United States	26

PB1463 Clinical Predictors of In-Hospital Mortality in Patients with Acute Pulmonary Embolism: 15-Years Experience in a Single Center in Argentina	25
PO16 Hemorrhagic Complications in Patients with Hemophilia A	24
PO04 SARS-CoV-2 Vaccinations and Risk of Venous Thrombosis - Case Control Study	24
PB1020 Simultaneous Generation of Thrombin and Plasmin in Patients with Deep Vein Thrombosis and High Levels of Lipoprotein (a)	22
PB0796 Interferon Treatment Suppresses in vitro NETosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms	22
PB0815 Involvement of the Nuclear Protein, TC2N, in Regulating VWF Levels in Endothelial Cells	22
PB0186 Results from BeneGene-1 Study: Prospective Collection of Bleeding Rate in Hemophilia B Patients Prior to Phase 3 Study (BeneGene-2) of Fidanacogene Elaparvovec	22
PB0249 Some Coagulation Profiles (PT, APTT, TT, FIB), Red Cell, Total White Cell, Platelet Counts and Their Indices Activity Levels in Persons Exposed to Wood Smoke (Firewood) in Calabar, Nigeria	22
PB0308 Anticoagulation Monitoring of UFH (Unfractioned Heparin) in a Pediatric Patient during Long Term ECMO (Extracorporeal Membrane Oxygenation)	21
PB0299 Surface Modification of Lung Assist Device for Neonates by Dual-Modification with Antithrombin-Heparin (ATH) and Tissue Plasminogen Activator (t-PA)	21
PB1060 Thrombin Generation and Fibrin Clot Structure in Nephrotic Patients with Primary Glomerular Disorders	21
PB1142 A Rapid Centrifugation 4000 g, 4 min Does not Impact Routine Coagulation Assays	20
PB0386 Increased Platelet Expression of the Transcriptional Suppressor ETV6 Can Be Detected by Immunofluorescence on the Blood Smear and Associates with ETV6-Related Thrombocytopenia	20
PB1140 Laboratory Features and Genotype of a Family with Heritable Dysfibrinogenaemia (HD)	20
PB0358 Hereditary Bleeding Disorders Web-Based Registry of Patients with Inherited Platelet Disorders	20
PB1117 Congenital Thrombotic Thrombocytopenic Purpura: Identification of Two Heterozygous Mutations in Splice Sites through NGS Sequencing	20
PB0403 A Common Variant in GRK5 Reveals a PAR1-Specific Regulation in Platelets	19
PB1385 Developing a Stem Cell-Based Model for Glanzmann Thrombasthenia to Explore VWF-GPIb Axis during Megakaryopoeisis	19
PB0612 COVID-19: Predictive Value of Methemoglobinemia	19
PB0412 Simulating the Impact of Thrombin on Platelet Function Requires Simultaneous Activation of Both PAR-1 and PAR-4	19
PB0627 Management of Invasive Procedures in Patients with Hemophilia A Receiving Emicizumab Prophylaxis: Real-World Data from a National Hemophilia Treatment Center	19
Intraindividual variability of von Willebrand factor and the need for repeated testing	18
Promise and pitfalls of viscoelastic testing for assessing blood hemostasis in ultraendurance sports	18
Effect of DNA methylation on inhibitor development in people with hemophilia A treated with FVIII concentrates	18
Rare inherited coagulation disorders: no longer orphan and neglected	18
Communication at diagnosis of venous thromboembolism: Lasting impact of verbal and nonverbal provider communication on patients	18
Contemporary trends in maternal outcomes during delivery hospitalizations among pregnancies complicated by von Willebrand disease—a cross-sectional analysis	18
Thrombo‐inflammatory biomarkers and D‐dimer in a biracial cohort study	18
Acquired von Willebrand syndrome in children	18
84 Rural Improvements in Venous Thrombosis Treatment in Oklahoma: The RIVETT-OK Initiative	17
140 Impact of Amiodarone Exposure on Apixaban Pharmacokinetics in Hospitalized Patients	17
Accumulating evidence for direct oral anticoagulants in liver disease	17
141 Heparin Management - The Ultimate Goldilocks Dilemma: A Quality Improvement Project	17
How do anticoagulants impact menstrual bleeding and quality of life? - The PERIOD study	17
How to use and report data on D‐dimer testing in the COVID‐19 era?	17
128 Evaluation of Heparin-Induced Thrombocytopenia Testing to Improve Anticoagulation Stewardship in an Acute Care Setting	17
Thrombophilia and outcomes of venous thromboembolism in older patients	17
Cryo‐EM structures of coagulation factors	16
Impact of antiplatelet therapy on hemostatic plug formation in the setting of thrombocytopenia	16
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality	16
Performance of risk scores in predicting major bleeding in left ventricular assist device recipients: a comparative external validation	16
Reevaluating thromboprophylaxis in COVID-19 outpatients: the case for a targeted, risk-based approach	15
Emicizumab prophylaxis in current haemophilia A care in the Czech Republic – data from the Czech National Haemophilia Programme Registry	15
Von Willebrand disease diagnosis: from complexity to simplicity	15
Blocking domain 6 of high molecular weight kininogen to understand intrinsic clotting mechanisms	15
Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China	15
OC 22.1 Proteome and Phosphoproteome Analyses of SARS-CoV-2 Infected Humanized ACE2 Mice Platelets Revealed Reprogramming of Platelets from Early Hyperreactive to Late Antiviral Phenotypes	14
PB0421 Phosphoproteomics and Systems Analysis Reveal Protein Kinase C Theta (PKCfɵ) Signaling Events Associated with the Generation of Procoagulant Platelets	14
Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany	14
HTRS2023.P2.16 Prevalence of iron deficiency in patients with inherited bleeding disorders	14

PB1193 Acute Myocardial Infarction Thrombi Show Fibrin Film that Increases with Ischaemia Duration	14
Advanced practice provider–led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilization	14
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people	14
HTRS2023.P2.3 F8 variants in women and girls evaluated for hemophilia A	14
PB0695 Comparison of Platelet Quality and Hemostatic Function Across Apheresis Collection Platforms	13
PB1519 Analysis of Aggregation Patterns Changes in Pregnant Women with Severe Preeclampsia	13
PB0723 Protease-Activated Receptor 4 Differentially Modulates TLR3- Dependent Responses In Vitro and In Vivo	13
PB0448 Fibrin Clot Properties Identify Patients that Benefit from Catheter- Directed Thrombolysis: A Post Hoc Analysis of the CAVA Trial	13
PB1383 RUNX1-Mutated Familial Platelet Disorder (RUNX1-FPD) with Associated Acute Myeloid Leukaemia - A Case/Family Series	13
PO26 Pulmonary Embolism in a Case with Thrombotic Thrombocytopenic Purpura after Plasmapheresis	13
OC 11.1 Development and Validation of a Clinical Prediction Model for the Diagnostic Management of Acute Pulmonary Embolism: An Individual Participant Data Meta-Analysis	13
PB1433 Opposing Effects of Canonical and Non-Canonical PAR-1 Activation in Experimental Diet-Induced Obesity and Fatty Liver Disease	13
PB1210 Incorporation of a2-Plasmin Inhibitor into Plasma Clots of Patients with Venous Thrombosis	13
PB1427 Reduced ADAMTS13 Activity in Staphylococcus Aureus Bacteremia is Associated with Neutrophil-Mediated Citrullination	13
PB0706 Mechanism by which Coagulation Factor XI Regulates Endothelial Cell Permeability and Barrier Function In Vitro and In Vivo	13
OC 03.4 A Common, Racially Diverse Protease Activated Receptor 4 Functional Variant Impacts Ischemic Stroke Outcomes: Evidence for a Pharmacogenetic Effect	13
PB1466 Early Mortality in Pulmonary Embolism - A Systematic Review and Analysis	13
PO19 Clinical Experiences in Managing the Transition to rIX-FP: Switching, Surgical Management and On-Demand	13
PB1377 Living with Glanzmann's Thrombasthenia: An Interim Report from the Glanzmann's 360 International Patient Survey	13
PB0437 Concordance of Phosphatidylserine/Prothrombin and APhL Antibodies Associated with Antiphospholipid Syndrome-Associated Pregnancy Morbidity	13
PB1133 DaXa, a Non-Calibrated Anti-FXa Assay that can be Used to Quantify DOAC Concentration in Acute Medical Emergencies	12
PB1152 Reporting of DOAC Concentration as FXa Inhibitory Units - Potential Solution for Smaller Laboratories?	12
PB1013 Evaluation of the Diagnostic Performance of Three D-Dimer Assays in Patients with Suspected Deep Vein Thrombosis	12
PB0117 COVID-Associated Thrombosis: New Insights	12
OC 75.3 Phenotype and Genotype Characterization of Patients with Congenital Fibrinogen Deficiencies: A Retrospective Analysis of the PRO-RBDD Database	12
PB0311 Anticoagulation in a Hypercoagulable Infant with End-Stage Renal Disease on Renal Replacement Therapies	12
PB1156 Clinical Performance Evaluation of the New Stago System for Fibrinogen and Thrombin Time Determination: sthemO Fib and sthemO Thrombin on sthemO 301 Analyzer	12
OC 72.5 Prediction of Venous Thromboembolism in Diverse Ancestry Populations Using Machine Learning and Electronic Health Records	12
PB0150 Fibrin Clot Formation is a Reliable Biological Marker to Evaluate FVIII Replacement Therapy in Hemophilia A Patients	12
PB1072 A Novel Factor VIII Specific APC Resistance Assay	12
PB1176 Analytical Performances Evaluation of the sthemO VWF:Ag Assay on the sthemO 301 Analyzer	12
PB1146 Comparison of Three Warfarin Monitoring Tests (PT, P&P and Fiix test) in Anticoagulated and Non-Anticoagulated Lupus Anticoagulant Positive Plasma Samples	12
PB0380 Corrections of Bernard Soulier Syndrome Megakaryocyte Phenotypes by Small Molecules and Interleukin-1α	12
PB0979 Significantly Increased CVC Replacement in Patients with Both Symptomatic and Incidental Venous Thrombotic Events in Pediatric Cancer Patients: A Population-Based Study	12
OC 70.2 The First Insight into the Spatial Structure of Human Kininogen by Cryogenic Electron Microscopy and Computational Methods	12
Regulation of megakaryo/thrombopoiesis by endosomal toll-like receptor 7 and 8 activation of CD34+ cells in a viral infection model	11
Probing rare von Willebrand disease–causing mutations in the D4 and C-domains of von Willebrand factor	11
OC 60.1 Delineating VonWillebrand Factor Genetic Variants in Patients with a Von Willebrand Disease Diagnosis	11
Recurrence risk of venous thromboembolism associated with systemic lupus erythematosus: A retrospective cohort study	11
Exploring heterogeneity in reported venous thromboembolism risk in COVID-19 and comparison to other viral pneumonias: a systematic review and meta-regression	11
PB0005 The Interest of the Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratio in the Prediction of Thrombus in Myocardial Infarction	11
Tissue factor-heparanase complex: intracellular nonhemostatic effects	11
Factor V variants in bleeding and thrombosis	11
OC 54.2 Comparison of Direct Oral Anticoagulants versus Low Molecular Weight Heparin in Primary and Metastatic Brain Cancers: A Meta-Analysis and Systematic Review	11
Joint health status in people with moderate hemophilia A: a cross-sectional multicenter study	10
Editorial Board	10
Lupus anticoagulant associates with thrombosis in patients with COVID‐19 admitted to intensive care units: A retrospective cohort study	10
Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients	10
Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay	10
Thrombin generation and implications for hemophilia therapies: A narrative review	10
Extracellular vesicle tissue factor and tissue factor pathway inhibitor are independent discriminators of sepsis-induced coagulopathy	10
Comparative Safety of Enoxaparin Versus Other Low-Molecular-Weight Heparins in Cancer-Associated Venous Thromboembolism: A Real-World Cohort Study from RIETE.	10
Neuraxial analgesia in pregnant individuals with bleeding disorders: a retrospective descriptive study of obstetric anesthesia practices and outcomes	10
Comparison of different algorithms for lupus anticoagulant detection: a single-center experience	10
Major bleeding and thromboembolism risks of antithrombotic treatment in patients with incident atrial fibrillation/flutter and a history of cancer	10
Lower early mortality and risk prediction improvement of obesity after acute pulmonary embolism: results from a multicenter cohort analysis with external validation	10
Interference of lupus anticoagulant causing antiprothrombin and anti–beta-2-glycoprotein I antibodies on international normalized ratio measurements: comparative analysis of international normalized r	10
Stroke prevention in atrial fibrillation with chronic kidney disease: a delicate balance of efficacy and safety considerations	10
Relevance of anti–platelet factor 4/heparin antibodies and platelet activation in systemic inflammatory diseases and thrombosis disorders: insight from the COVID-19 pandemic	10
Bedside exclusion of pulmonary embolism in children without radiation (BEEPER): a national study of the Pediatric Emergency Care Applied Research Network—Study protocol	10
Arthropathy on X-rays in 363 persons with hemophilia: long-term development, and impact of birth cohort and inhibitor status	10
Excluding pregnancy-associated deep vein thrombosis with whole-leg ultrasound	10
Estimating incidence of venous thromboembolism in COVID‐19: Methodological considerations	10
OC 77.1 Development, Validation, and Implementation of a Decision Support Tool for the Screening of Mild Bleeding Disorders	10
Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center	10
D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap	10
Effect of plasma levels of factor VIII according to procoagulant phospholipids on the risk of future venous thromboembolism	10
Galectin-3-binding protein and future venous thromboembolism	10
PB1263 Third Interim Subgroup Analysis of the Effectiveness and Safety of Damoctocog Alfa Pegol in Patients with Hemophilia A Treated Every 5 or Every 7 Days: Results from the Real-World HEM-POWR Stud	9
PB1153 Shortening of APTT when Heparin Neutralising Calcium Solution Replaces Calcium Alone is Highly Specific for the Presence of Heparin	9
Predictors of diagnostic delays and loss to follow-up in women with von Willebrand disease: a single-center retrospective cohort study	9
132 Antithrombotic Prescribing Practices in Patients with Atrial Fibrillation Presenting with Acute Ischemic Stroke while on Oral Anticoagulation	9
Managing surgical relapse risk in acquired thrombotic thrombocytopenic purpura: a systematic review	9
PB0908 Therapeutic Efficacy of Platelet-Rich Plasma in Chronic Compression of the Dorsal Root Ganglion in Rat	9
PB0452 Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro- Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism	9
PO34 The Risk of Vein Thromboembolism and Prevention in the Critically Illness Facilitated with an Electronic Decision Support System	9
PB0518 Novel Insights into Antifibrinolytic and Prothrombotic Functions of Lipoprotein(a)	9
Response to: “Are women equal? Considering impact of therapeutic abortion bans on science”	9
Hematopoietic stem cell transplantation in a newborn suffering from severe combined immunodeficiency and severe hemophilia A: a case report and review of the literature	9
PB0910 Evaluation of the Clot Formation Tranfusing Fresh, Cold and Frozen Platelets. Advantages for the Military Environment	9

PB1161 Evaluation of Three Prothrombin Time Reagents and their Sensitivity to Extrinsic Pathway Factor Deficiencies (FII, FV and FVII)	9
PB1527 Sticky Platelet Syndrome and Pregnancy Complications - 18 Years' Experience in National Center of Hemostasis and Thrombosis in Slovak Republic	9
PB0812 The Importance of the Amino-Acid Residue at Position 2561 in the C4-Domain of von Willebrand Factor	9
PB0233 Von Willebrand Disease in the East Mediterranean Region: Current Situation and Gaps	9
PB0865 Endothelial Extracellular Vesicles Regulate In Situ Pulmonary Thrombosis in Sickle Cell Disease	9
Issue Information	9
The diagnostic utility of genetic testing in inherited thrombocytopenia: regional multicenter tertiary experience	9
Changes in body mass index following venous thromboembolism in children: a prospective cohort study	9
PB0408 Regulation of Collagen Binding Integrins by Alpha 7 and C Helix	9
PO08 Factor XIII Deficiency as Underlying Cause of Unexplained Intracranial Hemorrhage	9
OC 60.5 Response to Desmopressin in Type 2N Von Willebrand’s Disease: A Genotype-Phenotype Analysis on a Cohort of 121 Patients	8
PB0708 The Tissue Factor/Thrombin Axis Limits Spontaneous Lymphatic Metastasis in Mice	8
OC 38.3 Effects of Apixaban Versus No Anticoagulation on Biomarkers of Thrombin Generation in Pediatric Acute Lymphoblastic Leukemia (ALL): A Biomarker Sub-Study of PREVAPIX-ALL, a Randomized Controll	8
PB0659 Patients with Hemophilia A have Increased Levels of Circulating Activated Protein C: Potential Contribution to their Hemostatic Status	8
PB0945 Effect of Drug Interactions with Apixaban on Clinical Outcomes in Cancer Patients with Venous Thromboembolism	8
PB0633 Understanding the Requirement for Additional Factor VIII Infusion Associated with Novel Haemophilia A Treatments: An Expert Elicitation Exercise	8
PB0047 COVID-19 Infection-Associated Platelet and Neutrophil Activation is Blunted by Previous Anti-SARS-CoV-2 Vaccination	8
PB1345 Health-Related Quality of Life Assessed by the SF-36 Health Survey in the Vienna ITP Biobank	8
PB1062 Exogenous Warfarin Intoxication Associated with Munchaüsen Syndrome	8
PB0707 Neutrophil Extracellular Traps Promote Cancer-Associated Inflammation and Myocardial Stress	8
PB1517 Effect of Uteroplacental Manipulation on Hemostatic Markers during Cesarean Delivery and Hysterectomy for Placenta Accreta Spectrum	8
OC 50.2 Low Dose FVIII Injections as a Potential Treatment to Prevent Inhibitor Development in Hemophilia a - an in Vivo Study	8
PB0699 Idarucizumab for Dabigatran Reversal: A Systematic Review and Meta-Analysis of Indications and Outcomes	8
HTRS2023.O8B.3 Elucidating the molecular mechanism of excessive phosphatidylserine exposure in sickle red cells	8
PB1059 Single Amino Acid Substitutions of an Antibody Specific for a Non-Active Site of Activated Protein C (APC) Yielded an Antibody Library Capable of Modulating and Uncoupling APC Pleiotropic Funct	8
PB0127 D-Dimer: Advantage Lost in the Post COVID Era?!	8
PB0545 The Effect of a History of Preeclampsia on Hemostatic Balance in the Non-Pregnant State	8
PB0319 Overexpression of ANKRD26 Results in Thrombocytopenia That May Exacerbate Clinical Phenotypes of Thrombotic Thrombocytopenic Purpura	8
OC 35.3 Correlation between ETP-Based APC Resistance and the Relative Risk of Venous Thromboembolism in Women Using Combined Oral Contraceptives	8
PB1461 Peri-Operative Venous Thromboembolism (VTE) Risk for Below Knee Amputations	8
PB0141 Characterizing the Transcriptomic Profile of Acquired Hemophilia Using RNA-Seq	8
OC 63.3 Combined Effect of High Factor VIII Levels and High Mean Platelet Volume on the Risk of Future Venous Thromboembolism	8
OC 42.2 Incidence and Risk Factors of Major Adverse Cardiovascular Events in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura during Remission	8
PB1424 PCF11 is a Central Hub in the Regulation of Inflammation in an Animal Model of Septicemia	8
PB0153 Evaluation of Cell Type-Specificity of Native Enhancer Elements from the F8 Locus	8
PB0644 Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study	8
PB0911 Platelet Reactivity in Patients with Atrial Fibrillation and Coronary Artery Disease under IIa Antagonists and Xa Antagonists	8
PB0595 The Profile of Contact Activation System Proteins in Human Abdominal Aortic Aneurysm Plasma-and Tissue Samples	8
PB0315 Characterizing Protease-Resistant ADAMTS13 Mutants	8
PB1388 Sticky Platelet Syndrome: Clinical Experience from a Tertiary Center	8
PB1520 Deep Learning Extracts Embedded Signatures Associated with Pregnancy and Preeclampsia from Circulating Vesicle Profiles	8
PB0837 Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status	7
A novel mechanism underlying allosteric regulation of ADAMTS-13 revealed by hydrogen−deuterium exchange plus mass spectrometry	7
Management of cancer‐associated thrombosis with thrombocytopenia: Impact of the ISTH guidance statement	7
PB1027 Delayed Diagnosis and Treatment of Deep Vein Thrombosis-an Underrecognized Factor for Its Related Complications?	7
Incidence rate of venous thrombosis in women switching combined oral contraceptives: a cohort study	7
Early SARS-CoV-2 infection: Platelet-neutrophil complexes and platelet function	7
OC 59.2 Analyzing Concizumab Mechanism of Action by a Mathematical Modeling Approach	7
OC 70.1 High Molecular Kininogen Cleavage in Cerebral Malaria	7
Hand grip strength in venous thromboembolism: risk of recurrence and mortality	7
Thromboprophylaxis in multiple myeloma	7
Welcoming 2023 with Gratitude	7
Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study	7
Recanalization and outcomes after cerebral venous thrombosis: a systematic review and meta-analysis	7
Platelet caspase‐1 and Bruton tyrosine kinase activation in patients with COVID‐19 is associated with disease severity and reversed in vitro by ibrutinib	7
Heavy or Healthy? Assessing Menstrual Bleeding and Bleeding Tendency in Dutch Adolescents	7
HTRS2023.P4.20 Systematic review of global hemostasis assays in myeloproliferative neoplasms: promising tools for biomarkers for hypercoagulability	7
Management of congenital dysfibrinogenemia in pregnancy: A challenging patient case	7
Aspirin nonsensitivity in patients with vascular disease: Assessment by light transmission aggregometry (aspirin nonsensitivity in vascular patients)	7
PB0994 Intronic Exploration of PROC in Patients with Unexplained Protein C Deficiencies	7
OC 27.2 Mechanistic Studies of Runt-Related Transcription Factor-1 (RUNX1)-Deficient Megakaryopoiesis and its Correction by RepSox (RS), a TGFβ-Receptor-1 Inhibitor	7
Cross-reacting antiporcine factor VIII inhibitors in patients with acquired hemophilia A	7
Hereditary thrombotic thrombocytopenic purpura and COVID‐19: Impacts of vaccination and infection inrare disease	7
OC 68.2 The Atlas of the Hemostatic RNA-Binding Protein Interactome	7
Antiphospholipid syndrome in rural, remote, and First Nations peoples in the Top End of the Northern Territory, Australia	7
Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies	7
OC 57.2 Integrated Proteomic and Computational Approach Reveals Determinants of Bleeding Risk in Factor XI Deficiency	7
Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)	7
The Evolution of Hemophilia Therapeutics: An Illustrated Review	7
Patients with metabolic dysfunction–associated steatotic liver disease have preserved in vitro responses to antiplatelet drugs	7
Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune‐mediated thrombotic thrombocytopenic purpura in the United States	7
Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing	7
Re: Hormonal therapies and venous thrombosis: The estrogen matters! Morimont et al.	7
OC 10.3 Platelets Mediate Intracranial Aneurysm Formation and Rupture in Mice	7
LB 01.4 Rare Germline Loss of Function Variants in SERPINH1 (HSP47) are Associated with Increased Risk of Thrombosis	7
Machine learning analysis of bleeding status in venous thromboembolism patients	7
Tranexamic acid for management of heavy vaginal bleeding: barriers to access and myths surrounding its use	7
OC 57.1 Peptidomics Reveals Expected and Unexpected Proteolytic Events in Plasma Upon Activation of the Coagulation Cascade	7
OC 65.3 Longread Nanopore Sequencing Reveal Novel Structural Variants in ITGB3, HPS5 and HPS3, Allowing Genetic Diagnosis of Glanzmann’s Thrombasthenia and Hermansky-Pudlak Syndrome in Four Unrelated	7
Underrepresentation and undertreatment of women in hematology: An unsolved issue	7
	7
How I respond to peer reviewer comments	7
Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes	7
Joint effect of ischemic stroke and obesity on the risk of venous thromboembolism: the Tromsø Study	7
Recombinant factor VIIa: new insights into the mechanism of action through product innovation	7
PB0763 Sudden Bilateral Deafness Revealing Anti Phospholipid Syndrome	6
Editorial Board	6
HTRS2023.P4.10 Endothelial ERp46 supports tissue factor activity	6
PB0574 Severe Bleeding in an Acquired Factor XIII Deficiency in an Otherwise Healthy Patient	6
PB0892 C-3399 Inhibitor of PDI Isoforms with an Attractive Profile of Antiplatelet Action	6
LB 01.5 Effect of the P-selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial	6
PB0798 Role of Platelets in Maintain Lung Hemostasis during dsRNA-Induced Acute Respiratory Distress Syndrome (ARDS) in Mice	6
PB0776 Characterization of the Effects of Hydroxyurea and Crizanlizumab on Plasma Immunothrombosis Biomarkers in Patients with Sickle Cell Disease	6
HTRS2023.O8A.3 Bringing PERT to pediatrics: implementing and examining outcomes of the first pediatric Pulmonary Embolism Response Team (PERT)	6
Title page	6